Barriers to mutational testing in patients with gastrointestinal stromal tumors (gist) – a survey of life raft group members

HIGHLIGHTS

SUMMARY

    Patients from 27 different countries participated, however the majority of patients (78%) were from the United_States (Fig 1D and Supplemental Table 1). The percentage of patients receiving a mutational test was significantly higher (p=0.03) for patients living in Europe where 26 of 27 (96.3%) patients reported having a test with other continents varying from 66.7% (South America) to 81.8% (Asia). As a result, the percentage of patients reporting having a mutational test in this survey was higher (80% n=237) than in the LRG registry (57% of living patients . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?